prodchem
Sep 8, 2026
The rapid development of gene therapy is placing new demands on pharmaceutical regulators and manufacturers. As advanced therapies move from research laboratories toward commercial development, authorities are exploring ways to make regulatory processes more efficient without reducing the standards applied to safety, quality and efficacy.
The US FDA introduced several initiatives in 2026 aimed at making cell and gene therapy development more flexible, including updated guidance covering chemistry, manufacturing and controls. The agency said these measures can help accelerate development while maintaining applicable regulatory requirements.
For manufacturers, faster pathways could shorten development timelines and improve access to innovative treatments. For procurement teams, the expansion of these therapies also creates new requirements around specialized raw materials, manufacturing controls, quality documentation and supply reliability.
Gene therapy products present regulatory challenges that differ from those associated with many conventional medicines. Their biological complexity, manufacturing processes and long-term safety considerations require specialized evaluation throughout development.
The EMA classifies gene therapy medicines within the broader category of advanced therapy medicinal products, alongside somatic cell therapies and tissue-engineered products. These products follow dedicated regulatory procedures and receive continued safety and efficacy monitoring after authorization.
Regulators therefore face a balancing exercise. They need to provide developers with enough flexibility to address rapidly evolving technologies while ensuring that clinical evidence remains sufficiently robust.
That balance becomes particularly important as more products enter development and regulators handle increasingly complex technologies.
The push for efficiency does not remove the need for rigorous evidence. Gene therapies can create long-lasting biological effects, making appropriate clinical, manufacturing and post-authorization monitoring particularly important.
The EMA's guidance for advanced therapies emphasizes reliable clinical evidence and protection of patient safety, dignity and well-being. It also recognizes that the distinctive characteristics of advanced therapies can affect how developers structure their development programs.
The FDA has taken a similar approach by introducing flexibility in certain manufacturing requirements while continuing to require applicable chemistry, manufacturing and controls standards. Its 2026 guidance specifically addresses how developers can apply flexibility while preparing products for biologics license applications.
For manufacturers, the objective is therefore more efficient regulation, not less rigorous regulation.
Gene therapy manufacturing can involve sophisticated biological processes, specialized facilities and tightly controlled production conditions. Consistency across batches becomes a central consideration because variations in manufacturing can affect product quality and clinical performance.
This makes chemistry, manufacturing and controls information particularly important. The FDA's 2026 guidance provides additional flexibility around CMC requirements for human cellular and gene therapy products, reflecting the agency's effort to accommodate the characteristics of these therapies.
Manufacturers may need to demonstrate control over:
Raw materials: Critical inputs must meet appropriate quality specifications and remain consistently available.
Manufacturing processes: Production steps need clear controls and reproducibility.
Product characterization: Developers need appropriate methods to demonstrate identity, quality and consistency.
Facility controls: Specialized environments must support reliable production.
Supply continuity: Changes in critical materials or suppliers can affect manufacturing processes.
These requirements create direct links between regulatory strategy and procurement management.
The growing number of advanced therapies has encouraged regulators to develop dedicated processes for classification, scientific advice and marketing authorization.
In Europe, the EMA provides specific support for ATMP developers, including scientific advice, protocol assistance, classification and other development services. The agency also provides a centralized authorization framework for advanced therapy medicines.
The EMA's ATMP classification procedure can help developers determine whether a product falls within the advanced therapy framework before marketing authorization. The agency states that its Committee for Advanced Therapies provides scientific recommendations on classification within a defined procedure.
These mechanisms can help companies identify regulatory expectations earlier. Earlier regulatory interaction can reduce uncertainty around development plans and potentially prevent costly changes later in the product lifecycle.
Regulatory timelines influence more than clinical development. They can affect investment decisions, manufacturing capacity planning and procurement commitments.
A company that expects a shorter pathway may need to prepare commercial-scale manufacturing earlier. That can increase demand for specialized equipment, production materials, packaging components and pharmaceutical-grade inputs.
For procurement managers, early planning can reduce the risk of shortages during manufacturing scale-up. Teams should understand which materials are critical to production and whether qualified alternatives exist.
Procurement planning should consider:
Supplier qualification: Determine whether suppliers meet the required quality standards.
Material consistency: Evaluate whether specifications remain stable across production lots.
Lead times: Identify materials that require long procurement cycles.
Dual sourcing: Develop alternative suppliers where regulations and product requirements permit.
Documentation: Maintain complete quality and regulatory records for critical materials.
Change management: Assess how supplier or material changes could affect the manufacturing process.
This becomes increasingly important as therapies progress from small clinical batches toward commercial production.
Traditional pharmaceutical supply chains often rely on established global sourcing networks. Gene therapy manufacturing can place greater emphasis on specialized inputs, controlled processes and traceability.
A supplier change that appears commercially attractive may require additional technical or regulatory assessment. Procurement teams therefore need closer coordination with quality assurance, manufacturing and regulatory affairs.
Supplier selection should consider more than price and delivery performance. Relevant factors can include:
Quality management systems.
Manufacturing consistency.
Technical documentation.
Traceability and batch records.
Change-control procedures.
Production capacity.
Geographic and logistical resilience.
The lowest-cost supplier is not necessarily the lowest-risk supplier when a material plays a critical role in an advanced therapy manufacturing process.
Efficient authorization does not end regulatory oversight. Advanced therapies can require continued monitoring after commercialization because regulators need to evaluate safety and effectiveness over time.
The EMA states that advanced therapy medicines continue to undergo safety and efficacy monitoring after authorization. It also provides scientific support for developers establishing pharmacovigilance and risk-management systems.
This creates a longer regulatory lifecycle than a simple approval event. Manufacturers need systems that can support ongoing monitoring, manufacturing consistency and appropriate responses to emerging safety information.
For supply chain teams, post-approval requirements can also influence material management. Changes to critical raw materials or production processes may require formal evaluation before implementation.
Early communication between developers and regulators can help identify technical problems before companies reach major submission milestones. Both the FDA and EMA provide structured guidance and support mechanisms for advanced therapy developers.
The EMA encourages developers to seek early advice at national or European level, particularly because advanced therapies have distinctive development characteristics.
The FDA's August 2026 guidance also addresses common questions across regulatory review, CMC, pharmacology, toxicology, clinical development and clinical pharmacology.
For manufacturers, this creates a clearer incentive to integrate regulatory strategy into product development from an early stage rather than treating regulatory review as a final checkpoint.
The expansion of gene therapy is likely to influence procurement as manufacturing moves toward larger-scale and more standardized production. Procurement teams will need to support faster development without compromising material quality or supply reliability.
Several priorities should remain on the procurement agenda:
Build qualified supplier networks: Maintain reliable sources for critical pharmaceutical manufacturing inputs.
Improve documentation: Keep specifications, certificates and quality records readily accessible.
Monitor supplier changes: Evaluate changes in manufacturing sites, processes or raw materials before they affect production.
Plan for scale-up: Anticipate material demand well before commercial manufacturing begins.
Coordinate across departments: Connect procurement decisions with quality, manufacturing and regulatory requirements.
These measures can help manufacturers respond when regulatory timelines accelerate unexpectedly.
The regulatory environment for gene therapy is evolving as authorities seek to support innovation while maintaining strong safeguards. The FDA's 2026 actions on cell and gene therapy development demonstrate a clear move toward greater flexibility in selected areas, particularly manufacturing requirements.
The EMA continues to operate specialized pathways for advanced therapies while emphasizing quality, safety and efficacy throughout development and post-authorization monitoring.
For pharmaceutical manufacturers, the opportunity lies in preparing for a regulatory system that is more responsive without assuming that standards will become less demanding. Companies that combine strong quality systems with flexible manufacturing and resilient procurement networks can respond more effectively as advanced therapies move toward commercialization.
For chemical and pharmaceutical suppliers, this evolution may create new demand for consistent, high-quality inputs and dependable documentation. Procurement teams that understand the regulatory requirements behind advanced therapy manufacturing will be better positioned to support developers as they move from clinical development into larger-scale production.
Featured Product
Found this useful?
Continue Reading
Pharmaceutical M&A is facing closer regulatory review as authorities examine competition, market concentration, intellectual property and patient access. Buyers need stronger due diligence and regulatory planning before completing cross-border transactions.
Chemical plastic recycling promises to turn difficult plastic waste into valuable feedstocks, yet commercial scale remains elusive. This analysis examines the economic, supply chain and market barriers keeping advanced recycling from matching industry ambitions.
New ownership structures can put sustainability higher on the agenda for chemical manufacturers, strengthening environmental compliance, emissions management and long-term ESG investment. Buyers and procurement teams should understand how ownership changes can reshape operational priorities and supplier expectations.
